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Abstract: Sphingolipids (SL) modulate several cellular processes including cell death, proliferation
and autophagy. The conversion of sphingomyelin (SM) to ceramide and the balance between
ceramide and sphingosine-1-phosphate (S1P), also known as the SL rheostat, have been associated
with oxidative stress and neurodegeneration. Research in the last decade has focused on the possibility
of targeting the SL metabolism as a therapeutic option; and SL levels in biofluids, including serum,
plasma, and cerebrospinal fluid (CSF), have been measured in several neurodegenerative diseases
with the aim of finding a diagnostic or prognostic marker. Previous reviews focused on results from
diseases such as Alzheimer’s Disease (AD), evaluated total SL or species levels in human biofluids,
post-mortem tissues and/or animal models. However, a comprehensive review of SL alterations
comparing results from several neurodegenerative diseases is lacking. The present work compiles
data from circulating sphingolipidomic studies and attempts to elucidate a possible connection
between certain SL species and neurodegeneration processes. Furthermore, the effects of ceramide
species according to their acyl-chain length in cellular pathways such as apoptosis and proliferation
are discussed in order to understand the impact of the level alteration in specific species. Finally,
enzymatic regulations and the possible influence of insulin resistance in the level alteration of SL
are evaluated.
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1. Introduction
Cell membranes are composed of several hundreds of different lipid species, having lipids
and proteins more or less restricted movements as a consequence of interactions between them and
cytoskeletal molecules [1]. Sphingolipids (SL) are structural components of membrane lipid bilayers
in eukaryotes and some prokaryotes. In particular, SL, together with cholesterol, participate in the
formation of membrane microdomains in the outer leaflet of the plasma membrane that are involved
in signal transduction and trafficking [2]. SL also play crucial roles as bioactive molecules in regulating
cellular processes including cell proliferation and migration, apoptosis, autophagy, differentiation,
senescence, and inflammatory responses [3–5]. For example, ceramide has been proposed to be a
second messenger in diverse cellular signaling pathways, with levels of ceramides being transiently
altered by several extracellular signals and physiological changes [6]. SL are highly enriched in
nervous cells and they exert specific roles in modulating cell signaling, controlling neuronal survival,
migration, and differentiation, responsiveness to trophic factors, synaptic stability and transmission,
and neuron-glia interactions [7]. For this reason, the nervous system is particularly vulnerable to SL
storage disorders [8]. Synaptic failure, even without major structural damage to neurons, seems to be a
key factor of neuronal physiological decline in sphingolipidoses [9].
Increased oxidative stress is a central event in neuronal failure that induces the activation of the
sphingomyelin (SM)-ceramide pathway, making SL key players in neurodegeneration. Moreover, the
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increase of ceramide formation from SM has been reported as specifically detrimental in neurons and
oligodendrocytes compared to astrocytes and microglia, which contain higher levels of antioxidant
defenses such as glutathione and manganese superoxide dismutase (MnSOD) [10]. The importance of
SL in regulating neuronal and glial survival has led researchers to investigate possible level alterations of
SL in neurodegenerative diseases. Biofluids such as plasma, serum, and to a lesser extent cerebrospinal
fluid (CSF) are accessible sources of biomarkers, and therefore, they are chosen by researchers when
investigating alterations of specific molecules in living patients with neurodegenerative diseases,
including retina pathologies. The purpose of this review is to summarize and to compare results
of lipidomics in biofluids of patients with neurodegenerative diseases, specifically those focused on
SL species or those that found SL levels altered compared with control individuals. For a broader
understanding, a brief explanation of selected lipid classes and enzymes involved in the SL metabolism
is provided. Finally, the possible implication of the changes in SL species in processes associated with
neurodegeneration, such as apoptosis, inflammation, and insulin resistance, are discussed, together
with the potential utility of sphingolipidomic studies in basic and clinical research.
2. Biosynthesis of Sphingolipids
SL are characterized by the presence of a common sphingoid backbone structure. Humans have
primarily sphingosine (d18:1), sphinganine or dihydrosphingosine (d18:0), and phytosphingosine or
4-hydroxysphinganine (t18:0) as sphingoid bases (Figure 1), and in small amounts the homologs d20:1,
d20:0, and 6-hydroxy-sphingosine (6-t18:1), the latter one in skin [11]. The synthesis of SL involves
enzymatic pathways in different cellular compartments, with ceramide playing a central role in SL
metabolism [12].
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Figure 1. Basic structures of sphingoid bases and sphingolipids more commonly measured in 
biofluids. The arrows indicate the anabolic/catabolic flux, with some of the enzymes mentioned in the 
text indicated as follows: CerS, ceramide synthase; SMase, sphingomyelinase. 
The de novo synthesis of SL starts in the endoplasmic reticulum (ER) with the condensation of 
mainly serine and palmitoyl-CoA by the rate-limiting membrane enzyme serine palmitoyltransferase 
(SPT) to form 3-ketodihydrosphingosine, which is then reduced to generate sphinganine. Ceramide 
synthases (CerS) catalyze the N-acetylation of sphinganine to form dihydroceramide which is 
converted to ceramide by the dihydroceramide desaturase. A second pathway termed “the salvage 
pathway” involves the degradation of complex SL such as gangliosides in the lysosome to generate 
ceramides and subsequently sphingosine by ceramidases. Sphingosine can also be N-acetylated by 
CerS in the ER to form ceramides again (Figure 1). 
CerS are a family of enzymes comprised of six isoforms with differential specificity towards 
acyl-CoAs as well as tissue and cell expression [13]. Figure 2 shows the fatty acid acyl-CoA length 
specificity of CerS (see also Table 1). The involvement of ceramide species in selected cellular 
processes is discussed below (see Section 6). Additionally, each tissue has a unique expression profile 
of CerS. For instance, high expression of CerS1 in human brains was observed by Jiang et al. [14], and 
later confirmed to be the highest expressed CerS in mouse brain, followed by an intermediate 
expression for CerS2 and CerS4, and a lower expression for CerS5 and CerS6 [15]. Alterations in brain 
CerS transcript levels have been also observed during development. CerS6 expression and ceramide 
(Cer) C16:0 content were shown to be decreased in the adult rat brain compared to postnatal P1 brain, 
while other ceramide species and most CerS expression levels were increased [16]. Similarly, 
decreased expression of CerS2 and CerS6 was observed during mouse brain development [17]. 
Figure 1. Basic structures of sphingoid bases and sphingolipids more commonly measured in biofluids.
The arrows indicate the anabolic/catabolic flux, with some of the enzymes mentioned in the text
indicated as follows: CerS, ceramide synthase; SMase, sphingomyelinase.
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The de novo synthesis of SL starts in the endoplasmic reticulum (ER) with the condensation of
mainly serine and palmitoyl-CoA by the rate-limiting membrane enzyme serine palmitoyltransferase
(SPT) to form 3-ketodihydrosphingosine, which is then reduced to generate sphinganine. Ceramide
synthases (CerS) catalyze the N-acetylation of sphinganine to form dihydroceramide which is converted
to ceramide by the dihydroceramide desaturase. A second pathway termed “the salvage pathway”
involves the degradation of complex SL such as gangliosides in the lysosome to generate ceramides
and subsequently sphingosine by ceramidases. Sphingosine can also be N-acetylated by CerS in the
ER to form ceramides again (Figure 1).
CerS are a family of enzymes comprised of six isoforms with differential specificity towards
acyl-CoAs as well as tissue and cell expression [13]. Figure 2 shows the fatty acid acyl-CoA length
specificity of CerS (see also Table 1). The involvement of ceramide species in selected cellular processes
is discussed below (see Section 6). Additionally, each tissue has a unique expression profile of CerS.
For instance, high expression of CerS1 in human brains was observed by Jiang et al. [14], and later
confirmed to be the highest expressed CerS in mouse brain, followed by an intermediate expression
for CerS2 and CerS4, and a lower expression for CerS5 and CerS6 [15]. Alterations in brain CerS
transcript levels have been also observed during development. CerS6 expression and ceramide (Cer)
C16:0 content were shown to be decreased in the adult rat brain compared to postnatal P1 brain, while
other ceramide species and most CerS expression levels were increased [16]. Similarly, decreased
expression of CerS2 and CerS6 was observed during mouse brain development [17]. Moreover, a
specific cell type expression was shown, with neurons presenting higher CerS1 expression, while CerS2
was predominantly expressed in myelinating cells of mouse brains [17]. In mouse retina, expression of
CerS1, CerS2, and CerS4 was detected, with CerS4 expressed in all retinal neurons and Müller cells [18].
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Figure 2. Ceramide synthases acyl-chain specificity. Venn diagrams show the results obtained for each 
of the six mammalian ceramide synthases (CerS) depending on the experimental approach: in vitro 
studies, overexpression or downregulation of CerS in cells, and selected tissues of CerS-deficient mice. 
WAT: white adipose tissue; ωOH: omega-hydroxylated acyl moieties. See more details in Table 1. 
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Figure 2. Ceramide synthases acyl-chain specificity. Venn diagrams show the results obtained for each
of the six mammalian ceramide synthases (CerS) depending on the experimental approach: in vitro
studies, overexpression or downregulation of CerS in cells, and selected tissues of CerS-deficient mice.
WAT: white adipose tissue;ωOH: omega-hydroxylated acyl moieties. See more details in Table 1.
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Table 1. Ceramide synthases acyl-chain specificity. Ceramide synthases (CerS) acyl-CoA preferences
for the synthesis of ceramides according to different experimental approaches.
Functional Studies in Cells In vitro Studies CerS-Deficient Mice Studies



















































































































*ωOH: omega-hydroxylated acyl moieties.
A third synthesis pathway involves the hydrolysis of SM in cellular membranes to form ceramide
and phosphorylcholine by sphingomyelinases (SMases). Several types of SMases have been described,
with acid SMase and Mg2+-dependent neutral SMase being the most extensively characterized [37]. The
acid SMase gene (SMPD1) encodes for a protein precursor that suffers differential protein modifications
and trafficking, producing both the lysosomal SMase (L-SMase), and the secretory SMase (S-SMase) [38].
The degradation of SM by the acid SMase is an important source of ceramides, and L-SMase is near
ubiquitously distributed in mammalian tissues, while acid SMase activity both from L-SMase and
S-SMase is present in several fluids such as serum, CSF, tears, and saliva [38]. An increase in S-SMase
activity in serum was observed to correlate with a parallel increase in several serum ceramide species
and particularly Cer d18:1/16:0 in patients with lymphohistiocytosis [39], showing the influence of this
enzyme in the content of circulating ceramides.
Ceramide can be later galactosylated in the ER to produce galactosylceramide (GalCer) or
glucosylated in the cis-Golgi to produce glucosylceramide (GlcCer) [40]. These cerebrosides with
distinct hexose moieties, i.e., galactose or glucose, are usually not distinguished in lipidomic studies and
termed hexosylceramides (HexCer). GlcCer can be translocated to the luminal leaflet of the Golgi and
trans-Golgi membranes, where addition of a galactose residue produces lactosylceramide (LacCer) [40]
(Figure 1). Also in the Golgi apparatus, 3-O-sulfation of the galactose residue in GalCer produces
3-O-sulfogalactosylceramide or sulfatide, a sulfated galactocerebroside particularly abundant in the brain
that participates in the formation of myelin sheath surrounding axons [41] (Figure 1). More complex SL
with different glycan structures are synthetized in cells, but were not reported in the studies summarized
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above and exceed the scope of this review. The most common SL detected in human biofluids are
ceramides, HexCer, SM, and ganglioside GM3 [42,43], though the levels of other SL such as sphinganine,
sphingosine, sphingosine-1-phosphate (S1P), and sulfatide have been reported [44,45].
A review on sphingolipids faces the problem of species notation depending on the knowledge of
the sphingoid base. The notation Cer C16:0 is sometimes used to include ceramides with different
sphingoid bases and a fatty acyl chain of 16 carbon atoms and no double bonds. In other cases, Cer
C16:0 is used exclusively for a ceramide with a sphingosine such as Cer d18:1/16:0, and dhCer C16:0
for a dihydroceramide with a sphinganine such as Cer d18:0/16:0. The method used for ceramide
detection has been checked for each publication cited in this review, and when possible to clearly
establish the sphingoid base, then a fatty acyl level notation (e.g., Cer d18:1/16:0) was used [46]. If it
was not possible, the simpler notation Cer C16:0 was kept. In certain cases, and for comparative
purposes, if it is not specified that the lipid measured or named is a dihydroceramide, the assumption
was made that Cer C16:0 is a synonym for Cer d18:1/16:0. This is properly clarified throughout the
review. Concerning SM species, when the sphingoid base is not known and the assumption that it has
two hydroxyl groups is made, then the lipid species level notation is used, e.g., SM 34:1, that may be
SM d18:1/16:0 and/or SM d18:0/16:1 [46].
3. Sphingolipids in Neurodegenerative Diseases: Case-Control Studies
Lipidomic studies in biofluids from patients with neurodegenerative diseases can be separated in
studies with a case-control design, and longitudinal studies that focus on finding specific lipid species
as predictors of a phenotypic characteristic or disease state (see Section 4).
Case-control studies have been carried out in several neurodegenerative diseases to find differences
in SL species, mostly analyzing plasma samples, and in some studies measuring lipids in serum or CSF
samples. In order to have a wider overview of possible changes in SL species in neurodegeneration,
these studies are compared even though lipids were obtained from different fluids. From the two major
classes of SL, some of the publications measured both ceramides and sphingomyelins, while others
focused on one lipid class. Lipidomic or sphingolipidomic studies that reported measurement of several
ceramide or SM species were included. Metabolomic studies that reported changes in one or two SL
are mentioned when appropriate, but not necessarily considered for the main comparison analyses.
Several of these studies reported level alterations on ceramide species with disease, allowing us
to try a first comparison of neurodegenerative associated modifications. For this purpose, data were
compiled from three studies in Alzheimer’s disease (AD) [45,47,48], and single studies in sporadic
Parkinson’s disease (PD) [49], multiple sclerosis (MS) [50], dementia with Lewy bodies (DLB) [45],
and age-related macular degeneration (AMD) [51]. It was assumed that ceramides and HexCer with
sphingosine (d18:1) base chain were reported in those studies in which it was not clarified (i.e., [45,49]).
Table 2 summarizes the main characteristics of the studies and their results. A common alteration in all
seven studies was an increase in Cer d18:1/16:0 in patients compared to controls (Figure 3 and Table 2).
Only two species measured in more than one study were consistently found elevated in patients:
HexCer d18:1/16:0 in MS, PD and AMD, and HexCer d18:1/18:1 in the same study that evaluated AD
and DLB patients compared to controls (Table 2). Cer d18:1/20:0 and d18:1/24:1 were found elevated
in AD patients in one or two of the three AD studies, respectively, and in DLB and PD patients. All
the other species were evaluated only in one study or were not consistently found altered in different
cohorts (Figure 3 and Table 2). The higher levels of ceramide species in plasma of AD patients is
in accordance with a previous study that observed higher content of total ceramides in CSF of AD
patients compared with the control group [52]. Likewise, a recent work that evaluated serum SL by
high-performance thin layer chromatography (HPTLC)-densitometry observed higher long and short
chain ceramides in AD compared to controls [53]. The consistency of results observed in plasma, serum
and CSF of AD patients supports the idea of a general biofluid increase in ceramide levels at least for
this disease. Therefore, it would be important to carry out more lipidomic studies and corroborate the
increase in ceramides observed in other neurodegenerative diseases.
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Table 2. Comparison of case-control lipidomic studies reporting alterations of ceramide species in neurodegenerative diseases.
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Platform ESI/MS/MS ESI/MS/MS UPLC/MS LC/ESI/MS/MS HPLC/ESI/MS/MS ESI/MS/MS ESI/MS/MS









Covariates no no yes # no no no yes ##
Multiple comparison’s correction no † no no no no no yes
Ceramides
Cer d18:1/16:0 ↑ ↑ ↑ ↑ (↑) ↑ ↑ (GA)
Cer d18:1/18:0 ‡ ns ns ↑ ns ns ns ns
Cer d18:1/20:0 ‡ ns ↑ ns ↑ ns ↑ ns
Cer d18:1/21:0 ↑
Cer d18:1/22:0 ns ns ↑ ns ns
Cer d18:1/23:0 ns ns
Cer d18:1/24:0 ns ns ns ns (↑) ns ns
Cer d18:1/26:0 ns ns
Cer d18:1/18:1 ns ↑ ↑
Cer d18:1/22:1 ns ns (↑)
Cer d18:1/24:1 ns ↑ ↑ ↑ ns ↑ ns
Cer d18:1/26:1 ns ↑
Cer d18:1/28:0, 23:1, 28:1, 22:2, 24:2, 28:2 ‡ ns
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Table 2. Cont.







Monohexosylceramides (Gluco- and Galactosylceramides)
HexCer d18:1/16:0 ↑ (↑) ↑
HexCer d18:1/18:0 ns ↑ ns ns
HexCer d18:1/20:0 ↑ ns
HexCer d18:1/22:0 ↑ ns
HexCer d18:1/24:0 ↑ ns
HexCer d18:1/26:0 ns
HexCer d18:1/16:1 ↑
HexCer d18:1/18:1 ↑ ↑
HexCer d18:1/22:1 ns (↑)
HexCer d18:1/24:1 ↑ ns ns ↑ ns
HexCer d18:1/26:1 ns
Lactosylceramides
LacCer 16:0, 18:0, 20:0, 24:0, 24:1 ↑
* Mini-Mental State examination (MMSE); ** National Institute of Aging (NIA)-Reagan Criteria; *** third report of the DLB consortium; # center of origin of the sample, gender, age, APOE
status, batch, internal standard; ## gender, age, batch. † q values (cumulative false discovery rates) re-evaluated. ‡ 2′-hydroxy N-acyl chain ceramides were also identified but no significant
differences were detected; OH_N16:0/N18:0 and OH_N19:1/N20:0 species were not resolved. CIS: clinically isolated syndrome; CNV: choroidal neovascularization; CSF: cerebrospinal
fluid; ESI: electrospray ionization; GA: geographic atrophy; HPLC: high performance liquid chromatography; LC: liquid chromatography; MS (in platform): mass spectrometry; PD-CN:
cognitively non-affected PD; PDD: PD-dementia; PD-MCI: PD-mild cognitive impairment; PPMS: primary-progressive MS; PRMS: progressive-relapsing MS; RRMS: relapsing-remitting
MS; UPLC: ultra-performance liquid chromatography. ↑: significantly increased in disease subjects; ns: non-significantly altered; (↑): increased in MS patients according to the authors, no
statistics performed. Empty cells indicate that the lipid species was not evaluated in the corresponding study.
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patients [47,53], and single studies of PD [54], MS [55], and amyotrophic lateral sclerosis (ALS) [56]. 
SM species were found decreased in AD, PD and MS compared to controls (Table 3). In mammals, 
the major sphingoid base is sphingosine (d18:1) [57]. If we assume sphingosine (d18:1) as the major 
sphingoid base for the studies in which sphingoid backbone was not identified, there were lower 
levels of SM d18:1/24:1 in patients compared to controls in the two AD and the MS studies (Table 3). 
In contrast with the results in other neurodegenerative diseases, ALS patients had elevated 
plasma levels of stearoyl SM (d18:1/18:0) compared to healthy controls in a metabolomics study of 
two independent cohorts of subjects [56]. This SL is a component of myelin sheath and may be 
reflecting its breakdown as part of motor neurons death [58]. Increased plasma levels of short chain 
SM were reported in AD compared to control subjects when evaluated by HPTLC, a result that was 
not corroborated in CSF using MALDI/MS-MS in the same study [53]. The comparison of results from 
Figure 3. Ceramides increased in biofluids of neurodegenerative diseases. Venn diagram showing
ceramide species found elevated in biofluids of patients suffering from neurodegenerative diseases
compared to controls. Overlapping areas indicate species commonly altered among groups. Notation
of ceramide species was simplified for the diagram (e.g., Cer C16:0 represents d18:1/16:0 ceramide).
AMD: age-related macular degeneration; CSF: cerebrospinal fluid; DLB: dementia with Lewy bodies.
See more details in Table 2.
While ceramides were consistently found increased in biofluids of patients, SM followed different
patterns, although the majority of studies showed decreased levels in neurodegenerative diseases.
Moreover, depending on the technique used to separate the molecules it is possible to identify the
sphingoid base of each SM species, and therefore it is difficult to compare results from different studies
at species level [46]. Table 3 shows the results obtained in two studies with AD patients [47,53], and
single studies of PD [54], MS [55], and amyotrophic lateral sclerosis (ALS) [56]. SM species were found
decreased in AD, PD and MS compared to controls (Table 3). In mammals, the major sphingoid base is
sphingosine (d18:1) [57]. If we assume sphingosine (d18:1) as the major sphingoid base for the studies
in which sphingoid backbone was not identified, there were lower levels of SM d18:1/24:1 in patients
compared to controls in the two AD and the MS studies (Table 3).
In contrast with the results in other neurodegenerative diseases, ALS patients had elevated
plasma levels of stearoyl SM (d18:1/18:0) compared to healthy controls in a metabolomics study of
two independent cohorts of subjects [56]. This SL is a component of myelin sheath and may be
reflecting its breakdown as part of motor neurons death [58]. Increased plasma levels of short chain
SM were reported in AD compared to control subjects when evaluated by HPTLC, a result that was
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not corroborated in CSF using MALDI/MS-MS in the same study [53]. The comparison of results
from different body fluids and the use of two different analytical techniques make it difficult to
identify the reason of the discrepancy. Our lipidomics study using serum samples of AMD and control
subjects observed also an increase in SM 42:2 and 42:3, possibly SM d18:1/24:1 and 24:2, specifically in
geographic atrophy (GA) patients compared to controls although correction for multiple comparisons
made the differences not significant [51]. This kind of correction was not done by all the studies
evaluated in this review, and they would be important to be introduced in future analyses.
Table 3. Comparison of case-control lipidomic studies reporting alteration of sphingomyelin (SM)
species in neurodegenerative diseases.







Reference [47] [53] [54] [55] [56]
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Covariates no no age, gender no no
Multiple comparison’s
correction no
† no yes no yes
Sphingomyelins
Sphingoid base not identified:N-linked fatty acid
SM N17:1, 18:0, 24:2 ns
SM N20:0, 21:0, 22:0, 23:0,
24:0, 22:1, 23:1, 24:1 ↓
Sphingoid base not identified: Hydroxyl Group Level
SM d30:1, 32:1, 39:1 (↓)
Sphingoid base identified
SM d18:1/13:0, 14:0, 16:0, 16:1
(9Z)(OH) ↓
SM d18:1/18:0 ↑
SM d18:1/24:1 (15Z) ↓ ↓
SM d18:2/20:0, 22:1 ↓
* Mini-Mental State examination (MMSE). † Q values (cumulative false discovery rates) were evaluated. CIS: clinically
isolated syndrome; CSF: cerebrospinal fluid; ESI: electrospray ionization; LC: liquid chromatography; MALDI:
matrix-assisted laser desorption/ionization; MS (in platform): mass spectrometry; PPMS: primary-progressive
MS; QTOF: quadrupole time-of-flight; RRMS: relapsing-remitting MS; UHPLC: ultra high performance liquid
chromatography. Statistics. PLS-DA: partial least square-discriminant analysis; RF: random forest. ↑/↓: significantly
increased/decreased in disease subjects; ns: non-significantly altered; (↓): SM species significantly altered between
controls and PD patients according to the PLS model, but with p-values > 0.05 in subsequent Welch’s t-test or
Wilcoxon test false discovery rate (FDR) adjusted. Empty cells indicate that the lipid species was not evaluated in
the corresponding study.
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SL other than ceramide and SM have been found to be altered in neurological diseases. For
example, Zhang et al. [59] showed higher plasma levels of ganglioside-n-acetylneuraminic acid-3 in
patients with PD compared with control subjects. This lipid is a glycosphingolipid that serves as
precursor to brain-abundant complex gangliosides, and higher plasma levels may be associated with
reduced glucocerebrosidase activity previously reported in nervous system of PD patients [60]. Several
studies reported changes in one or two SL classes in neurological diseases by techniques other than
omics, but their enumeration is beyond the scope of this review.
4. Longitudinal Studies Evaluating SL as Predictors of Neurological Phenotypes or
Disease Incidence
The Women’s Health and Aging Study II carried out in Baltimore is a population-based longitudinal
study of older women followed up to nine years, and used by Mielke and coworkers [44,61] to evaluate
baseline serum levels of SM and ceramide species as predictors of subsequent cognitive impairment, or
to find associations with an increased risk of all-cause dementia and AD. Researchers showed that total
SM and Cer d18:1/16:0, 18:0, 22:0, 24:1, 24:0, and sulfatide were suited to predict impairment on delayed
memory recall, Cer d18:1/16:0, 20:0, and 22:0 predicted impairment on immediate memory recall, and
higher levels of Cer d18:1/16:0, and 20:0 were associated with decreased psychomotor speed [44].
Moreover, Cer d18:1/16:0, 24:0, and LacCer were associated with a higher risk of AD [61]. In contrast,
the Baltimore Longitudinal Study of Aging showed no association between ceramide levels and risk of
AD in women, but demonstrated that higher levels of SM d18:1/16:0, and 22:1 at baseline reduced the
risk of AD for this gender [62]. Among men, higher levels of Cer d18:1/16:0, 18:0, 22:0, and 24:0, and SM
d18:1/18:0, 18:1, 20:1, and 22:1 were associated with increased risk of developing AD [62]. Interestingly,
higher contents of Cer d18:1/16:0 have been consistently associated with neurodegeneration both in
case-control and longitudinal studies.
A serum non-targeted metabolomics approach of samples from mild cognitive impairment
(MCI) and age-matched AD subjects showed that sphinganine-1-phosphate (dihydro-S1P) can predict
the conversion of MCI to probable AD [63]. Both S1P and dihydro-S1P act extracellularly via S1P
receptors, although S1P but not dihydro-S1P plays an intracellular specific role as suppressor of
apoptosis [64]. Further research is needed to understand the possible influence of dihydro-S1P levels
in neurodegeneration.
5. Sphingolipids at the Site of Neurodegeneration
The changes in SL levels observed in plasma and CSF may be reflecting alterations in nervous
tissues undergoing degeneration. In accordance with the results observed in plasma, AD patients
presented elevated levels of ceramides, and in some cases GlcCer and GalCer, compared with control
donors in white matter of temporal cortex and cerebellum [65], pre frontal cortex (PFC) [66], middle
frontal gyrus, which is a brain region with extensive Aβ plaques and neurofibrillary tangles, and in
isolated membranes from brain tissue samples [67]. Other studies evaluated changes in SL levels in
specific disease-associated structures or cell types. Astroglia with ceramide-immunoreactivity was
detected in frontal cortices of AD brains but not control brains, and this reactivity colocalized with
senile plaques [52]. A later study showed a specific enrichment of senile plaques in saturated ceramides
Cer d18:1/18:0 and Cer d18:1/20:0 with respect to adjacent plaque-free neuropil [68].
In the anterior cingulate cortex (ACC) of PD patients a shift from Cer d18:1 longer (C24:1, C23:0,
C22:0) to shorter (C16:0, C18:0, C18:1, C20:0) acyl chain composition was observed compared to control
ACC [69]. These shifts in the composition of ceramide fatty acids may be associated with regulation of
CerS or SMase. CerS1 is the prevalent ceramide synthase in the brain [70], resulting in Cer d18:1/18:0
being the predominant ceramide species in the central nervous system, while CerS2 is expressed
in neurons and in oligodendrocytes during the myelination process [71]. CerS2 null mice showed
decreased levels of very-long-chain (VLC) Cer d18:1/24:0 and 24:1 with a compensatory increase in Cer
d18:1/16:0 and 20:0 in the brain [71]. The increase in brain tissue of Cer d18:1/16:0 is in accordance
Int. J. Mol. Sci. 2019, 20, 3564 11 of 20
with the finding that this ceramide species was found elevated in most of the case-control studies
(Figure 3). Regarding SM levels in AD brains compared with controls, it was shown that there was
a down-regulation of long-chain (LC) SM (d18:0/20:0 and d18:1/20:0) and upregulation of VLC SM
(d18:1/22:1 and d18:1/26:1) in PFC, a reduction in LC SM levels (including d18:0/18:0, d18:1/16:1, and
d18:1/18:0) in the entorhinal cortex (ERC) [66], and of SM d18:1/24:0 levels in middle frontal gyrus [67].
In general, decreased levels of biofluid SM species were reported in AD and other neurodegenerative
diseases (Table 3).
Brain SL are also abundant in the monounsaturated nervonic acid (24:1n-9) in comparison with
other tissues, and the proportion of this LC fatty acid was reported to be lower in white matter and
myelin samples of MS donors compared with controls [72], similarly to the lower levels of SM d18:1/24:1
and other SM species observed in MS CSF samples (Table 3). This is in accordance with the fact that
MS pathology involves demyelination of axons and oligodendrocyte loss [73]. No changes in SM,
ceramide and HexCer species with nervonic acid were observed in the gray matter of mid-frontal
cortex in the brain of subjects with AD compared with control subjects [74], although higher levels
of Cer and HexCer and lower SM containing nervonic acid were detected in AD biofluids (Tables 2
and 3). In the same manner, it was previously reviewed that levels of cerebrosides and sulfatide were
found increased, decreased or unchanged in AD brains compared with controls depending on the
sample being taken from cortex or hippocampus, white or gray matter [75]. This may be associated
with the specific pathology affecting certain brain structures, and/or with the sample preparation [43].
Interestingly, Satoi and coworkers [52] demonstrated that retinoblastoma NB2a cells undergoing
apoptosis due to treatment with retinoic acid presented higher ceramides and SM content inside the
cells, and a specific extracellular release of ceramide but not SM. This differential release of SL species
may influence the inconsistency observed in the tendency of SM levels in neurodegeneration. Further
studies are necessary to understand these discrepancies.
6. Specific Regulation and Properties of Lipid Species According to Fatty Acid Chain
Most of the lipidomic studies presented in this review showed Cer d18:1/16:0 associated with
disease or cognitive impairment. Lipid micelles containing Cer C16:0, and to a lesser extent Cer C24:0,
were shown to induce oxidative stress and decrease neuronal maximal respiratory rate and the spare
respiratory capacity in primary rat hippocampal neurons, while Cer C22:0 or no addition of ceramide
had no effect [50]. Accordingly, ceramides with fatty acyl chains of 16 and 24 carbon atoms were
shown to induce apoptosis of neutrophils via caspase activation [76], and Cer d18:1/16:0 has been
associated with TNF-alpha-induced apoptosis in rodent hepatocytes [77]. Cer C16:0 conjugated with
BSA was also found to cause cell death in a dose dependent manner in mouse retina-derived 661W
cells [78]. Another study that used a novel technique termed traceless ceramide ligation demonstrated
that Cer d18:1/16:0 or 18:0 delivered into HeLa cells resulted in a reduction of cell viability compared
to sphingosine, while no reduction was observed with monounsaturated Cer d18:1/18:1 or 24:1 [79].
Grösch et al. [80] hypothesized that the capacity of Cer C16:0 to mix well with cholesterol and
therefore influence the functionality of lipid rafts may explain the ability of ceramide-enriched platforms
to activate both intrinsic and extrinsic apoptotic pathways. On the other hand, Cer C24:0 does not
mix properly with cholesterol, which may explain its proliferative effects [81,82]. Following the same
tendency, another study demonstrated that the BCL-2 family member BAK is required for generation
of LC ceramides (C16-C18), but not VLC ceramides (C24), and the subsequent induction of apoptosis
as a consequence of the formation of mitochondrial ceramide-rich domains that is involved in the
BAX/BAK translocation [83].
As suggested before, regulation of SMases may cause the alteration of SL species observed in
neurodegeneration. A recent study in a chronic psychosocial stress mice model, which is a risk factor
for inflammatory disorders and major depressive disorder among others, showed that stressed mice
presented an increase in hepatic and S-SMase activity and increased Cer d18:1/16:0 and decreased Cer
d18:1/24:0 content in the liver [84]. In patients with hemophagocytic lymphohistiocytosis, a systemic
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inflammatory syndrome, serum S-SMase activity was elevated compared to controls, with a parallel
increase of Cer d18:1/16:0, but a decrease of Cer d18:1/24:0 concentrations [39]. Interestingly, it was
shown in MCF7 breast carcinoma cells that IL-1β induced up-regulation of S-SMase secretion and
increased the selective production of Cer d18:1/16:0 and d18:0/16:0, whereas higher L-SMase activity
was associated with a selective increase in VLC ceramides such as Cer d18:1/26:1, suggesting distinct
metabolic roles for each acid SMase [85]. Finally, Pieragostino et al. [55] suggested that the decrease in
SM species observed in MS patients compared to controls (Table 3) may be a consequence of the higher
acid SMase activity and the number of acid SMase enriched exosomes in CSF of MS patients, which
correlated with disease severity.
The shifts from VLC to LC ceramides in patients and mice models has been also suggested
to be a consequence of a balance or compensation in CerS activities. A study using HeLa cells
demonstrated that knockdown of CERS2 produces a shift in ceramide composition from C24 to C16
species conferring greater susceptibility to apoptosis induced by cisplatin, UV, or C6 ceramide [86].
Similarly, an inter-regulation of SL species was demonstrated by knockdown of CerS in MCF-7 cells.
Downregulation of CerS2 resulted in decreased levels of Cer containing C22–C24 saturated and
monounsaturated fatty acids, but a large increase in SL containing C16:0, and to a lesser extent C14:0
and C18:0 fatty acyl chains. On the other hand, CerS6 knockdown decreases Cer d18:1/16:0 and
d18:0/16:0 [22]. Down-regulation of CerS2 in SMS-KCNR neuroblastoma cells causes decrease in VLC
Cer d18:1/24:0 and 24:1 and increase in LC Cer d18:1/14:0 and 16:0, accompanied with activation of the
unfolded protein response (UPR), induction of autophagy and growth arrest, but not apoptosis [87].
The authors also showed that the increase of LC ceramides in CerS2-down-regulated cells may be
caused by reverse ceramidase activity of alkaline ceramidases 1 and 2 that catalyze the synthesis
instead of the hydrolysis of ceramides, but not by CerS5 and CerS6 activities [87].
However, to what extent the fatty acyl chain of ceramides is responsible of certain cellular
responses is still under discussion. CerS1-deficient mice presented decreased levels of Cer d18:1 with
C18 acyl chain length and increased levels of species with other acyl chains, i.e., C16, C20, C22, and
C24, compared to wild-type mice, and these changes were accompanied with neuronal apoptosis in
the cerebellum [26]. In older mice, the authors also detected an elevation of free sphingosine and
sphinganine levels [26], and in a further study they suggested that the accumulation of these sphingoid
bases rather than the reduction in C18 ceramides, may cause the observed neuronal death [88].
7. Ceramides and Insulin Resistance in Neurodegeneration
Ceramides have been associated with the development of insulin resistance [89]. Obese humans
presented elevated CERS6 mRNA expression and Cer C14:0, C16:0, C16:1, C18:0, C18:1, and C22:1 levels
in adipose tissue compared to lean subjects, and a correlation between increasing CERS6 expression
and insulin resistance [90]. Accordingly, Cer d18:1/18:0, 20:0, 24:1, and total ceramide levels were
higher in obese subjects with type 2 diabetes compared to lean healthy controls, and ceramide levels
correlated with the severity of insulin resistance [91]. Cer d18:1/16:0 was not measured in the later
study. A connection between circulating ceramides and skeletal muscle insulin sensitivity has been
proposed in obese and type 2 diabetes patients [92,93], with LDL-ceramide as a possible linker between
the liver and muscles [94], an important association that may explain elevation of biofluid SL in disease.
Similar to the observations in humans, CerS6-deficient mice showed reduced Cer C16:0 content and
protection from high-fat diet-induced obesity and glucose intolerance [90], while CerS5 knock-out mice
under a high-fat diet exhibited a reduction of Cer d18:1/16:0 in white adipose tissue and improved
glucose tolerance compared to wild type mice [35]. A recent study evaluated hepatic lipids in about 100
genetically diverse inbred strains of mice fed on a high-fat/high-sucrose diet, and found that females
were less insulin resistant but had higher Cer d18:1/16:0 levels than males, and only Cer d18:1/20:0
levels were increased in males and were associated with insulin resistance specifically for this sex [95].
Insulin resistance has also been implicated in some of the neurodegenerative diseases reviewed
here in which higher circulating ceramide levels were reported. The hippocampus has a high glucose
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demand and is an insulin-sensitive tissue, making it susceptible to insulin resistance during aging [96].
Accordingly, abnormalities in glucose regulation and insulin resistance are chronic metabolic disorders
that have been recognized to contribute to late onset AD [97,98]. In this context, high glycemic index
(GI) of the diet and diabetes have been implicated as risk factors for AMD [99,100]. Although the
uptake of glucose in retinal pigment epithelium (RPE) cells is not insulin-dependent, the signaling
pathways modulated by the insulin receptor (IR) in RPE cells regulate the generation of reactive
oxygen species and the expression of pro-inflammatory cytokines in mice retina [101]. Considering that
ceramide is proposed to mediate insulin-resistance in skeletal muscle by blocking Akt signaling [94], it
may be possible that higher ceramide levels in AMD influence the retinal homeostasis in part through
an alteration of insulin signaling in the RPE. This may also impact insulin-dependent activation of
mammalian target of rapamycin (mTOR) in RPE, which is implicated in cellular metabolism, protein
synthesis, and cellular growth, among other processes [102]. On the other hand, it was demonstrated
that the photoreceptor, inner nuclear and ganglion cell layers of frog and rat retinas express the insulin
stimulated-glucose transporter Glut4 [103], although a study of Glut transporters in the human eye
failed to detect Glut4 expression [104].
8. Conclusions and Perspectives
The main goal of this review was to have an outlook on SL alterations in biofluids of
neurodegenerative diseases. A common finding in all the studies evaluated was an increase in
ceramide species in different biofluids of patients compared to controls, with Cer d18:1/16:0 as the
main species altered in a recurrent manner. These results evince that individual ceramide species
may be considered general markers of neurodegeneration, rather than disease specific. However,
it might be useful to make use of standardized methods for the measurement of SL in biofluids so
as to enable the subsequent analysis of a common panel of SL species by innovative bioinformatics
tools and to find disease-specific patterns. In this regard, two recent studies applied multivariate and
bioinformatic analyses to differentiate between healthy individuals and patients according to several
SL species. After applying unsupervised machine-learning to analyze serum concentrations of three
lipid classes from MS patients and healthy controls, Lötsch et al. [105] found that the data structures
emerging from the ceramide species analysis were able to be almost completely distinguished between
the two groups of individuals, with about 95% of accuracy. In another work, unsupervised methods
of data structure detection demonstrated that seven plasma SL mediators were able to diagnose
dementia with an accuracy of 77%, in contrast to the 65% or less accuracy obtained by using random
lipid markers [106]. A later analysis by Lötsch et al. [107] combined eight lipid species, including
three SL, a lysophospholipid, an eicosanoid, a pterin and two endocannabinoids, reaching a high
accuracy of 96% to detect the presence or absence of MS. These kinds of methodologies may be useful
to establish alteration patterns according to specific diseases, or disease types. Our study in AMD
showed that Cer d18:1/16:0, and to a lesser extent SM 42:2 and 42:3, were increased specifically in
GA patients, while HexCer d18:1/16:0 was increased in GA and choroidal neovascularization (CNV)
patients compared to controls [51]. These differences between GA and CNV together with alterations
in other SL species are likely to contribute to specific disease types patterns. Glycosphingolipids have
been previously implicated in angiogenesis, the process that causes vessel proliferation in patients
with CNV. Inhibition of LacCer synthase expression in human umbilical vein endothelial cells was
shown to inhibit angiogenesis [108], and the use of antibodies against globotriaosylceramide inhibited
tumor-induced angiogenesis in mouse neoplastic lesions [109]. It would be interesting to measure
more complex glycoceramides in AMD patients to verify if LacCer or other glycosylated ceramides are
specifically increased in CNV and may be regarded as possible therapeutic targets or neovascularization
prognostic markers.
The results from sphingolipidomics in biofluids are also useful so as to understand mechanisms
involved in the pathogenesis of diseases and their connection to other markers such as genetic and
environmental factors. We found that genetic variants in CFH and ARMS2 genes may influence the
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association between Cer d18:1/16:0 and AMD, whereas genetic variants in genes involved in lipid
transport and metabolism such as APOE, LIPC, and LPL may not [51]. Han et al. [47] showed that
AD patients carrying APOE4 allele(s) had lower plasma SM levels than those with other isoforms,
although this association was not present in controls. Similar results had previously been observed
in ApoE4 AD brains, in which lower SM and higher ceramide and sulfatide levels were reported in
comparison with ApoE3 AD brains, a tendency that was not replicated in brain tissues from normal
subjects [110]. Therefore, although validations are needed, associations observed between plasma
lipids and genetic variants may have a correlation in the tissues undergoing neurodegeneration.
Technical limitations for the comparison of SL levels in biofluids have arisen from the use of
different platforms that are able to measure different panels of SL classes and species. Furthermore, the
understanding and comparison of SM results were complicated by the non-identification of sphingoid
bases. In order to translate findings to clinical approaches, such as disease specific SL patterns, common
analytical methods need to be considered in the future.
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